Year-End Review | Vickor Medical's Major Milestones and Product Highlights in 2024

As of the end of 2024, the company has D-shufo^®Patent Foramen Ovale (PFO) Occluder, etc.5 Class III Medical DevicesThe product has been approved for registration by the National Medical Products Administration (NMPA); the core product, D-shufo New Generation PFO Occluder, has been completed.Implantation in Over 100 Hospitals Across China and the First Overseas Implantation, demonstrating excellent clinical feedback, highlighting broad application potential and clinical value.

D-SHVAD™ Interventional Ventricular Assist System, led by Vickor Medical Suzhou Subsidiary in development, successfully completedChina's First Case of High-Risk Percutaneous Coronary Intervention (PCI) Under Ventricular Assist Support, marking the company's successful entry into the field of active devices for structural heart disease.

ContinuousWuKey Special Projects for Achievement Transformation in Han City, Key R&D Plan of Hubei Province, Top Ten Medical-Engineering Cross Results of Hubei Province, and Other Provincial and Municipal Key Scientific and Technological Research Plans。The project is led by Vickor, with the deep involvement of an academician team and multiple partner organizations jointly carrying it out. It truly practices the "industry-academia-research" integrated model to break through key bottleneck technologies, supporting the company’s technological R&D and innovative applications.

Multiple pipelines advancing simultaneously, the DOCS VALVE independently developed by the company^®The transcatheter aortic valve replacement system has completed the FIM trial and officially entered the multi-center clinical trial in China. The atrial shunt device, a pioneering product in China, has completed the one-year follow-up of its clinical trial with significant clinical outcomes, and registration is planned to be submitted soon.

"PFO Occluder and Cardiac Occluder Delivery System"Successfully Passed the EU MDR On-site Audit；All of the company's fully marketed products have passed the ISO9001 quality management system certification, accelerating the pace of overseas market access.

As a key investment-attracted enterprise in Liangxi District, Wuxi City, Vickor Qi Yuan (Wuxi) Medical Technology Co., Ltd. was established and announced.Comprehensively Enter the Market of Cardiac Active Medical DevicesWuxi Qiyuan, as the company's second headquarters, undertakes core functions such as the company's subsequent blockbuster product development, global marketing center, and capital market planning.

Focusing on core intellectual property and patent achievements, in 2024, nearly 20 domestic and international invention patents have been applied for and obtained, including the appearance design of the transcatheter aortic valve replacement system.German Red Dot Design Award; Multiple R&D projects have won awards in several competitions, including the Wuhan Future Industry Innovation Competition and the "Maker China" Hubei Competition.Grand Prize, First Prizeand many other honors; Wuhan Association for Science and Technology established a "Science and Technology Innovation Expert Workstation" at Vickor and presented the plaque.

Attention from Multiple Levels of Leadership within the Nation and ProvinceThe main leaders of the National Medical Products Administration and the Provincial Medical Products Administration inspected Vickor to guide the work, highly recognized the company's R&D innovation achievements, and showed great concern for the company’s clinical registration needs. Vice Governor Chen Ping of the Hubei Provincial Government, while investigating financial work in Wuhan East Lake High-tech Development Zone, expressed high recognition for the scientific and technological innovation work and capital market performance of Wuhan Vickor Medical Technology Co., Ltd. Together, we look forward to more of Vickor's globally innovative products being transformed, launched, and promoted in the market soon.

Successfully Completed C-round Financing of Several Hundred Million YuanLed by Bohua Capital, a well-known investment institution in Wuxi, Jiangsu, this funding will provide strong financial support for Vickor in areas such as product development, market expansion, and international strategic layout. The news was successively reported by several important media outlets, including Xinhua News Agency and Yangtze River Daily, marking the largest single financing round in Hubei Province's medical device sector this year.

By the end of 2024, the company achieved its first commercial year, with sales reaching in just six months.Tens of Millions in Performance BreakthroughThe successful completion of the "entry into regulation" marks the company's transformation from a small and medium-sized enterprise to a profitable large-scale enterprise. At the same time, Vickor Medical continues to be awarded the title of "Golden Seed for IPO Reserve Enterprises" in Hubei Province, reflecting the expectations and confidence of leaders at the provincial, municipal, and district levels in the company’s potential for going public.

In 2024, Vickor Medical achieved remarkable results and significant accomplishments in talent work! The three co-founders,Chairman Shang Xiaoke Awarded the Title of "National Outstanding Young Physician," General Manager Wang Xueli Selected as "Wuhan Government Special Allowance Expert," and Chief Technology Officer Chen Song Granted the "Wuhan Talent" Title; Sun Ming, the director of the company's R&D center, was awarded the "Outstanding Young Talent of Optics Valley 3551," and all R&D personnel have achieved technical titles of intermediate or advanced level and above, showcasing the company's philosophy of valuing, cherishing, and nurturing talent.